H. Daley

发表

An immunogenic personal neoantigen vaccine for patients with melanoma

Charles H. Yoon, Shuqiang Li, N. Lennon, 2017, Nature.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Alyssa R. Richman, Monika S. Kowalczyk, Shuqiang Li, 2018, Nature.

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

D. Neuberg, N. Munshi, G. Dranoff, 2018, Cancer Immunology Research.

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

G. Dranoff, J. Ritz, S. Nikiforow, 2018, Cytotherapy.

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

E. Winer, G. Dranoff, M. Mihm, 2022, Breast Cancer Research and Treatment.

A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.

N. Munshi, J. Ritz, S. Nikiforow, 2016 .

Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

G. Linette, F. Hodi, A. Sober, 2005, Clinical Cancer Research.

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.

David A. Williams, S. Pai, J. Ritz, 2020, The New England journal of medicine.

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.

K. Anderson, J. Ritz, B. Yeap, 1987, The New England journal of medicine.

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

Martin F. Mihm, E. Winer, G. Dranoff, 2022, Breast Cancer Research and Treatment.

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial

A. Giobbie-Hurder, G. Dranoff, J. Ritz, 2017, Clinical Cancer Research.

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma

Charles H. Yoon, Shuqiang Li, N. Lennon, 2018, Nature.

Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma

J. Friedberg, D. Neuberg, T. Spitzer, 2003, Bone Marrow Transplantation.

Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia.

D. Neuberg, G. Pinkus, A. Freedman, 1993, Blood.

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

Matthew J. Frigault, A. Jakubowiak, S. Nikiforow, 2022, Blood advances.

CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation.

J. Ritz, A. Freedman, H. Daley, 2006, Cytotherapy.

Early neutrophil engraftment following autologous BMT provides a functional predictor of long‐term hematopoietic reconstitution

J. Gribben, J. Ritz, D. Zahrieh, 2003, Transfusion.

Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow.

J. Ritz, A. Freedman, L. Nadler, 1987, Blood.

CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study

D. Neuberg, R. Soiffer, R. Champlin, 2004, Bone Marrow Transplantation.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients.

David A. Williams, J. Manis, S. Nikiforow, 2018, Blood advances.

Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients

David A. Williams, J. Ritz, J. Manis, 2018, Blood.

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation

J. Ritz, S. Nikiforow, P. Armand, 2016, Haematologica.

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

Catherine J. Wu, F. Hodi, G. Dranoff, 2021, Blood advances.

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease

D. Fisher, R. Soiffer, E. Milford, 2004, Bone Marrow Transplantation.

Validation of short‐term handling and storage conditions for marrow and peripheral blood stem cell products

J. Ritz, S. Spellman, C. Vierra-Green, 2011, Transfusion.

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

David A. Williams, D. K. Wood, E. Schonbrun, 2019 .

Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy

J. Gribben, D. Neuberg, J. Ritz, 2004, Transfusion.

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.

M. Mihm, G. Dranoff, J. Ritz, 2017, Blood advances.

Abstract CT540: A phase 1 trial of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy with IL-15 superagonist in advanced head and neck cancer: Part 1 results

J. Ritz, S. Nikiforow, R. Soiffer, 2022, Cancer Research.

Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020 .

Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

D. Neuberg, N. Munshi, G. Dranoff, 2016 .

Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

Matthew J. Frigault, M. Sabatino, M. Bishop, 2020, Blood.

Epstein‐Barr virus‐specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma

J. Ritz, L. Wirth, J. Lorch, 2017, Cancer.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Alyssa R. Richman, Monika S. Kowalczyk, Shuqiang Li, 2018, Nature.

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

S. Nikiforow, H. Daley, D. Chand, 2024, Nature communications.

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

N. Munshi, J. Laubach, J. Ritz, 2021, Blood.

Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safety

A. Kheirkhah, R. Dana, J. Ritz, 2023, Science advances.